Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</title><author><name sortKey="Johnstone, Timothy C" sort="Johnstone, Timothy C" uniqKey="Johnstone T" first="Timothy C." last="Johnstone">Timothy C. Johnstone</name></author><author><name sortKey="Suntharalingam, Kogularamanan" sort="Suntharalingam, Kogularamanan" uniqKey="Suntharalingam K" first="Kogularamanan" last="Suntharalingam">Kogularamanan Suntharalingam</name></author><author><name sortKey="Lippard, Stephen J" sort="Lippard, Stephen J" uniqKey="Lippard S" first="Stephen J." last="Lippard">Stephen J. Lippard</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26865551</idno><idno type="pmc">4792284</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792284</idno><idno type="RBID">PMC:4792284</idno><idno type="doi">10.1021/acs.chemrev.5b00597</idno><date when="2016">2016</date><idno type="wicri:Area/Pmc/Corpus">000323</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000323</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</title><author><name sortKey="Johnstone, Timothy C" sort="Johnstone, Timothy C" uniqKey="Johnstone T" first="Timothy C." last="Johnstone">Timothy C. Johnstone</name></author><author><name sortKey="Suntharalingam, Kogularamanan" sort="Suntharalingam, Kogularamanan" uniqKey="Suntharalingam K" first="Kogularamanan" last="Suntharalingam">Kogularamanan Suntharalingam</name></author><author><name sortKey="Lippard, Stephen J" sort="Lippard, Stephen J" uniqKey="Lippard S" first="Stephen J." last="Lippard">Stephen J. Lippard</name></author></analytic><series><title level="j">Chemical reviews</title><idno type="ISSN">0009-2665</idno><idno type="eISSN">1520-6890</idno><imprint><date when="2016">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing non-classical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore non-classical platinum(II) complexes with trans geometry and with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-treat agents, and photoactivatable platinum(IV) complexes. Nanodelivery particles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations including supramolecular self-assembled structures, proteins, peptides, metal-organic frameworks, and coordination polymers will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also reflect our optimism that the next generation of platinum cancer drugs is about to arrive.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">2985134R</journal-id><journal-id journal-id-type="pubmed-jr-id">2913</journal-id><journal-id journal-id-type="nlm-ta">Chem Rev</journal-id><journal-id journal-id-type="iso-abbrev">Chem. Rev.</journal-id><journal-title-group><journal-title>Chemical reviews</journal-title></journal-title-group><issn pub-type="ppub">0009-2665</issn><issn pub-type="epub">1520-6890</issn></journal-meta><article-meta><article-id pub-id-type="pmid">26865551</article-id><article-id pub-id-type="pmc">4792284</article-id><article-id pub-id-type="doi">10.1021/acs.chemrev.5b00597</article-id><article-id pub-id-type="manuscript">NIHMS751367</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Johnstone</surname><given-names>Timothy C.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Suntharalingam</surname><given-names>Kogularamanan</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lippard</surname><given-names>Stephen J.</given-names></name></contrib></contrib-group><pub-date pub-type="nihms-submitted"><day>15</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>11</day><month>2</month><year>2016</year></pub-date><pub-date pub-type="ppub"><day>9</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>3</month><year>2016</year></pub-date><volume>116</volume><issue>5</issue><fpage>3436</fpage><lpage>3486</lpage><pmc-comment>elocation-id from pubmed: 10.1021/acs.chemrev.5b00597</pmc-comment>
<abstract><p id="P1">The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer,, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing non-classical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore non-classical platinum(II) complexes with trans geometry and with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-treat agents, and photoactivatable platinum(IV) complexes. Nanodelivery particles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations including supramolecular self-assembled structures, proteins, peptides, metal-organic frameworks, and coordination polymers will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also reflect our optimism that the next generation of platinum cancer drugs is about to arrive.</p></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0003239 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0003239 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.21. |  |